Faecal proteomics: A tool to investigate dysbiosis and inflammation in patients with cystic fibrosis

Debyser, Griet; Mesuere, Bart; Clement, Lieven; Weygaert, Jens Van de; Hecke, Pieter Van; Duytschaever, Gwen; Aerts, Maarten; Dawyndt, Peter; Boeck, K. De; Vandamme, Peter; Devreese, Bart

doi:10.1016/j.jcf.2015.08.003

Cited by 76 publications

(82 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results differ from the findings of a recent study that applied a metaproteomic approach to analyze CF fecal samples, and reported reduced proteins taxonomically attributed to butyrate-producing bacteria and increased proteins associated with R. gnavus and Clostridia species (Debyser et al. 2016). Further investigations are required to explain these discrepancies.…”

Section: Resultsmentioning

confidence: 99%

Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota

Miragoli

Federici

Ferrari

et al. 2016

FEMS Microbiology Ecology

View full text Add to dashboard Cite

Cystic fibrosis is often associated with intestinal inflammation due to several factors, including altered gut microbiota composition. In this study, we analyzed the fecal microbiota among patients with cystic fibrosis of 10–22 years of age, and compared the findings with age-matched healthy subjects. The participating patients included 14 homozygotes and 14 heterozygotes with the delF508 mutation, and 2 heterozygotes presenting non-delF508 mutations. We used PCR-DGGE and qPCR to analyze the presence of bacteria, archaea and sulfate-reducing bacteria. Overall, our findings confirmed disruption of the cystic fibrosis gut microbiota. Principal component analysis of the qPCR data revealed no differences between homozygotes and heterozygotes, while both groups were distinct from healthy subjects who showed higher biodiversity. Archaea were under the detection limit in all homozygotes subjects, whereas methanogens were detected in 62% of both cystic fibrosis heterozygotes and healthy subjects. Our qPCR results revealed a low frequency of sulfate-reducing bacteria in the homozygote (13%) and heterozygote (13%) patients with cystic fibrosis compared with healthy subjects (87.5%). This is a pioneer study showing that patients with cystic fibrosis exhibit significant reduction of H2-consuming microorganisms, which could increase hydrogen accumulation in the colon and the expulsion of this gas through non-microbial routes.

show abstract

Section: Resultsmentioning

confidence: 99%

Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota

Miragoli

Federici

Ferrari

et al. 2016

FEMS Microbiology Ecology

View full text Add to dashboard Cite

show abstract

“…These metagenomic alterations correlated with both fecal fat content and measures of inflammation, suggesting that enteral lipid abundance may enrich for pro‐inflammatory microbiota in children with CF. This model is supported by observations from clinical trials of probiotics in CF patients, as will be discussed in more detail below, as well as from a study of bacterial and host proteins (i.e., using proteomics) in CF fecal samples …”

Section: Relationship Between Gi Microbiota and Cf Gi Diseasementioning

confidence: 61%

The CF gastrointestinal microbiome: Structure and clinical impact

Rogers

Narkewicz

Hoffman

2016

Pediatric Pulmonology

View full text Add to dashboard Cite

Summary The gastrointestinal (GI) microbiome is shaped by host diet, immunity, and other physicochemical characteristics of the GI tract, and perturbations such as antibiotic treatments can lead to persistent changes in microbial constituency and function. These GI microbes also play critical roles in host nutrition and health. A growing body of evidence suggests that the GI microbiome in people with CF is altered, and that these dysbioses contribute to disease manifestations in many organs, both within and beyond the GI tract. Therapies that people with CF receive, even those targeting the respiratory tract, may impact the CF GI microbiome in ways that can influence the outcome of treatment. These new perspectives on the microbial contents of the CF intestine offer new opportunities for preventing a variety of CF-associated disorders.

show abstract

“…The microbiome, which is often called the 'forgotten organ', is essential for maintaining human health and physiology, but has now been associated with several diseases including cancer, IBD, coeliac disease, obesity, cardiac disease, psoriasis, asthma, autism, [33] CDI, and cystic fibrosis. [34] While earlier studies used mainly genomic-or transcriptomic-based approaches, faecal proteomics is now filling a new niche. [35] The initial non-targeted, shotgun MS/ MS-based metaproteomics study of the faecal microbiome used stool samples from two identical twins.…”

Section: The Faecal Microbiomementioning

confidence: 99%

The Wonderful World of Poo: The Turdome and Beyond

Nice¹

2020

Aust. J. Chem.

View full text Add to dashboard Cite

Defecate: it is something we all do, it is something we joke about, yet for many in real life it is a subject that is taboo. However, it is now being realised that faeces are a veritable scientific goldmine, have many potential uses, and may even save your life! In this article I will review the history behind the use of faecal material and look at some of its emerging playing fields, in particular its role in medical diagnosis. I will discuss faecal proteomics and other omics technologies (Proteogenomics: The Omics Pipeline), including studies on the microbiome, in order to understand, diagnose, and treat gastrointestinal tract pathologies and other diseases, and show how these technologies will play a role in the move towards personalized medicine.

show abstract

Faecal proteomics: A tool to investigate dysbiosis and inflammation in patients with cystic fibrosis

Abstract: Faecal metaproteomics provides insights in intestinal dysbiosis, inflammation in patients with CF and can be used to monitor different disease markers in parallel.

Cited by 76 publications

References 31 publications

Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota

Impact of cystic fibrosis disease on archaea and bacteria composition of gut microbiota

The CF gastrointestinal microbiome: Structure and clinical impact

The Wonderful World of Poo: The Turdome and Beyond

Contact Info

Product

Resources

About